ACTIVITY OF THE PAN-HER TYROSINE KINASE (TK) INHIBITOR DACOMITINIB (PF-00299804) IN REFRACTORY NONADENOCARCINOMA (NON-A) NON-SMALL CELL LUNG CANCER (NSCLC) AND COMPARED WITH ERLOTINIBIN THE 2ND-/3RD-LINE SETTING
المؤلفون الرئيسيون: | Blackhall, F, Gadgeel, S, Reckamp, K, Talbot, D, Barrios, C, Krzakowski, M, Liang, J, O'Connell, J |
---|---|
التنسيق: | Journal article |
منشور في: |
2012
|
مواد مشابهة
-
Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer.
حسب: Ramalingam, S, وآخرون
منشور في: (2012) -
Pre-clinical characterization of Dacomitinib (PF-00299804), an irreversible pan-ErbB inhibitor, combined with ionizing radiation for head and neck squamous cell carcinoma.
حسب: Justin P Williams, وآخرون
منشور في: (2014-01-01) -
Efficacy of dacomitinib in patients with EGFR‐mutated NSCLC and brain metastases
حسب: Jinyao Zhang, وآخرون
منشور في: (2021-12-01) -
Clinical evaluation of dacomitinib for the treatment of metastatic non-small cell lung cancer (NSCLC): current perspectives
حسب: Lavacchi D, وآخرون
منشور في: (2019-09-01) -
Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutation: an ambispective cohort study
حسب: Xingxiang Pu, وآخرون
منشور في: (2023-10-01)